Abstract
Cancer therapy has witnessed major advances in the last few decades. However, the conventional therapies have a narrow therapeutic application, and the responses produced are generally unpredictable and are often non-curative. New strategies to combat cancer are being developed, one of the most promising of which is the use of non-genotoxic chemicals that are able to rescue the tumor suppressor function of p53 in cancer cells. In this review, we first discuss: (i) the current knowledge on the role of p53 in determining the fate of human normal and malignant cells following exposure to cancer therapeutic agents; and (ii) the biological consequences of the failure of cancer cells to implement p53-mediated responses in terms of development of highly metastatic “karyoplasts” which exhibit both selfrenewal and treatment-resistant properties. We next provide an update on the potential anticancer properties of diverse types of pharmacological modulators of p53, including histone deacetylase inhibitors (e.g., trichostatin A), aromatase inhibitors (e.g., Anastrozole), and the nuclear export inhibitor leptomycin B. In addition, we highlight the various shortcomings of in vitro assays that are universally used for preclinical evaluation of anti-neoplastic properties of new drugs, and describe alternative cytotoxicity assays that circumvent some of these shortcomings.
Keywords: p53 signaling, pharmacological modulators of p53, cancer therapy, cytotoxicity assays, apoptosis, accelerated senescence
Current Signal Transduction Therapy
Title: Pharmacological Modulation of p53 Function in Cancer Therapy
Volume: 3 Issue: 3
Author(s): Razmik Mirzayans and David Murray
Affiliation:
Keywords: p53 signaling, pharmacological modulators of p53, cancer therapy, cytotoxicity assays, apoptosis, accelerated senescence
Abstract: Cancer therapy has witnessed major advances in the last few decades. However, the conventional therapies have a narrow therapeutic application, and the responses produced are generally unpredictable and are often non-curative. New strategies to combat cancer are being developed, one of the most promising of which is the use of non-genotoxic chemicals that are able to rescue the tumor suppressor function of p53 in cancer cells. In this review, we first discuss: (i) the current knowledge on the role of p53 in determining the fate of human normal and malignant cells following exposure to cancer therapeutic agents; and (ii) the biological consequences of the failure of cancer cells to implement p53-mediated responses in terms of development of highly metastatic “karyoplasts” which exhibit both selfrenewal and treatment-resistant properties. We next provide an update on the potential anticancer properties of diverse types of pharmacological modulators of p53, including histone deacetylase inhibitors (e.g., trichostatin A), aromatase inhibitors (e.g., Anastrozole), and the nuclear export inhibitor leptomycin B. In addition, we highlight the various shortcomings of in vitro assays that are universally used for preclinical evaluation of anti-neoplastic properties of new drugs, and describe alternative cytotoxicity assays that circumvent some of these shortcomings.
Export Options
About this article
Cite this article as:
Mirzayans Razmik and Murray David, Pharmacological Modulation of p53 Function in Cancer Therapy, Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699721
DOI https://dx.doi.org/10.2174/157436208785699721 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options
Current Pharmaceutical Design Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics Inhibiting TLR9 Signaling Stimulates Apoptosis and Cell Cycle Arrest, and Alleviates Angiogenic Property in Human Cervical Cancer Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Applications of Molecularly Imprinted Polymers for Isolation of Estrogens from Environmental Water Samples
Current Analytical Chemistry Oncostatin M: Potential Implications for Malignancy and Metabolism
Current Pharmaceutical Design Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Current Molecular Medicine Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Hypoxia and Oxidative Stress in the Pathogenesis of Gynecological Cancers and in Therapeutical Options
Current Cancer Therapy Reviews Total Synthesis and Bioactivity of ent-homospisulosine and N,O-diacetylhomoclavaminol A
Current Organic Chemistry High Throughput Screening of Normal and Neoplastic Tissue Samples
Combinatorial Chemistry & High Throughput Screening